Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
Arq Bras Cardiol. 2009 Sep;93(3):299-306. doi: 10.1590/s0066-782x2009000900015.
Percutaneous aortic valve replacement for the treatment of aortic stenosis is an available and efficient alternative for patients at high surgical risk, especially those with advanced age and comorbidities.
The authors report the first experience made in our midst with the use of the CoreValve endoprosthesis.
In January 2008, two patients underwent percutaneous aortic valve replacement due to symptomatic aortic stenosis. They were selected for being elderly (77 and 87 years) and presenting comorbidities and a high surgical risk (EuroScore 7.7% and 12.1%).
Percutaneous implantations of the CoreValve device were successfully performed. Enlargement of the valve area (from 0.7 to 1.5 cm(2) and from 0.5 to 1.3 cm(2)) and reduction of the aortic transvalvular gradient (from 82 to 50 mmHg and from 94 to 31 mmHg) were observed immediately after the intervention. During hospital stay, permanent pacemaker implantation was required in both patients due to atrioventricular block. At six months, an even greater drop in the aortic transvalvular gradient (gradient < 20 mmHg) and remission of symptoms of heart failure (NYHA III to NYHA I) were observed.
The use of the CoreValve endoprosthesis for the treatment of aortic stenosis proved to be feasible and showed encouraging results in this early experience made in our midst.
经皮主动脉瓣置换术治疗主动脉瓣狭窄是一种可行且有效的方法,适用于高手术风险的患者,尤其是高龄和合并症较多的患者。
作者报告了在我们中心首次使用 CoreValve 瓣膜假体的经验。
2008 年 1 月,两名有症状的主动脉瓣狭窄患者接受了经皮主动脉瓣置换术。选择他们是因为他们年龄较大(77 岁和 87 岁)且存在合并症和高手术风险(EuroScore 分别为 7.7%和 12.1%)。
成功地进行了 CoreValve 装置的经皮植入。瓣膜面积(从 0.7 厘米 2 增加到 1.5 厘米 2 和从 0.5 厘米 2 增加到 1.3 厘米 2)和主动脉瓣跨瓣梯度(从 82 毫米汞柱降至 50 毫米汞柱和从 94 毫米汞柱降至 31 毫米汞柱)在干预后立即得到改善。在住院期间,由于房室传导阻滞,两名患者均需要植入永久性起搏器。6 个月时,主动脉瓣跨瓣梯度进一步降低(梯度<20 毫米汞柱),心力衰竭症状缓解(NYHA III 级至 NYHA I 级)。
在我们中心的早期经验中,使用 CoreValve 瓣膜假体治疗主动脉瓣狭窄是可行的,并且结果令人鼓舞。